Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
Condition(s):Metastatic Breast CancerLast Updated:April 27, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Metastatic Breast CancerLast Updated:April 27, 2023Active, not recruiting
Condition(s):Metastatic Renal Cell CarcinomaLast Updated:May 8, 2023Recruiting
Condition(s):Breast CancerLast Updated:March 3, 2023Recruiting
Condition(s):Metastatic Breast CancerLast Updated:February 21, 2023Completed
Condition(s):Early Breast CancerLast Updated:February 16, 2023Active, not recruiting
Condition(s):Oligometastatic Renal Cell CarcinomaLast Updated:August 30, 2023Recruiting
Condition(s):Metastatic Breast Cancer; Triple Negative Breast Cancer; PD-L1 Gene MutationLast Updated:February 1, 2024Active, not recruiting
Condition(s):Renal Carcinoma MetastaticLast Updated:January 6, 2021Recruiting
Condition(s):Metastatic Breast Cancer; Locally Advanced Breast CancerLast Updated:March 23, 2020Unknown status
Condition(s):Chemotherapy-induced Nausea and VomitingLast Updated:April 3, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.